Werewolf Therapeutics

Update in progress

HOWL (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Werewolf Therapeutics, Inc. is a biopharmaceutical company developing immune-stimulating therapies for cancer and immune diseases. Using its PREDATOR platform, it creates conditionally activated INDs to improve safety and efficacy. Lead candidates include WTX-124 (IL-2 INDUKINE) and WTX-330 (IL-12 INDUKINE) for solid tumors. Additional programs target IFN-α, IL-10, IL-21, IL-18, STEAP1, and CDH6. Founded 2017, based in Watertown, MA.

Company score

Sentiment: -0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.06; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive